Development of novel small molecule inhibitor of androgen receptor to treat castration-resistant prostate cancer
Androgen receptor (AR), a transcription factor, is a validated therapeutic target for prostate cancer. All current AR-targeting therapies inhibit the growth of prostate cancer cells by blocking the ligand-binding domain (LBD), where androgen binds to activate the receptor. Unfortunately, these thera...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2015
|
| Online Access: | http://hdl.handle.net/2429/54492 |